Astellas Pharma Profit Margin

The latest profit margin for ALPMF is 16.16% as of June 2026. That compares with 4.19% in the prior-year period — up 285.4% year over year. That is above the Healthcare sector average of 10.58%. Investors often review this figure alongside Astellas Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALPMF's profit margin moved from 4.19% to 16.16% — a 285.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Astellas Pharma's valuation or profitability profile.

Against Healthcare companies, ALPMF currently prints 16.16% for profit margin, while the sector average sits near 10.58%. That is roughly 52.8% above the sector mean. Large gaps often invite a closer look at Astellas Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Astellas Pharma converts resources into returns. At 16.16%, ALPMF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 4.19% in the prior-year period — up 285.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ALPMF's profit margin (16.16%), review year-over-year change from 4.19%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.